We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 21, 2021

Adjuvant Pharmacogenomic-Driven Chemotherapy in Completely Resected Stage II–IIIA NSCLC

Annals of Oncology


Additional Info

Annals of Oncology
International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung Cancer
Ann. Oncol 2021 Oct 05;[EPub Ahead of Print], S Novello, V Torri, C Grohe, S Kurz, M Serke, T Wehler, A Meyer, D Ladage, M Geissler, I Colantonio, C Cauchi, E Stoelben, A Ceribelli, C Kropf-Sanchen, G Valmadre, G Borra, M Schena, A Morabito, A Santo, V Gregorc, R Chiari, M Reck, G Schmid-Bindert, G Folprecht, F Griesinger, A Follador, P Pedrazzoli, A Bearz, O Caffo, NJ Dickgreber, L Irtelli, G Wiest, V Monica, L Porcu, C Manegold, GV Scagliotti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading